Breast CancerNCT05036096
Cone Beam Breast CT for Breast Cancer Screening
A study testing CBBCT Imaging and Digital Mammography in people with Breast Cancer, run by Koning Corporation at 4 sites in United States.
Trial summary
Up to one thousand and twenty-eight (1028) patients from screening and diagnostic population will be enrolled and consented to participate in the study to create an enriched data set. These women will be enrolled from annual screening population and diagnostic workup population. Read more about this study
- Who is it for?
- Ages 30 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer
- What is being tested?
- CBBCT Imaging and Digital Mammography
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,024 participants
- Where
- 4 sitesUnited States
- Study dates
- 30 Oct 2021to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Screening Group:
- Female sex of any ethnicity
- Age 40 years or older
- Scheduled for a routine screening mammography exam within 4 weeks.
- Diagnostic Group:
- Female sex of any ethnicity
Show all 9Show fewer
- Age 30 years or older
- Have an abnormality detected by Breast Self Exam (BSE), or Clinical Breast Exam (CBE), or have an abnormality detected by an imaging modality.
- Will undergo diagnostic mammography, prior to breast biopsy (if needed).
Who cannot join
- Pregnancy
- Lactation
- Unknown pregnancy status AND
- has refused pregnancy testing and
- has refused to sign a pregnancy test waiver
- Women who are unable or unwilling to understand or to provide informed consent
Show all 17Show fewer
- Women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker.
- Women who are unable to tolerate study constraints.
- Women who have received radiation treatments to the thorax or breast area for malignant and nonmalignant conditions, such as (but not limited to):
- Treatment for enlarged thymus gland as an infant
- Irradiation for benign breast conditions, including breast inflammation after giving birth
- Treatment for Hodgkin's disease
- Women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
- Women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to):
- Tuberculosis
- Severe scoliosis Additional exclusion criteria due to machine limitations
- Patient's body weight is over the limit of the scanner table (440 lbs. or 200kg)
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Women's Imaging Specialists
Dacula, Georgia, 30019
Knoxville Comprehensive Breast Center
Knoxville, Tennessee, 37909
Port Orange Imaging Center
Port Orange, Florida, 32129
The Howard Center for Women's Health
Tifton, Georgia, 31794
About this study
Up to one thousand and twenty-eight (1028) patients from screening and diagnostic population will be enrolled and consented to participate in the study to create an enriched data set. These women will be enrolled from annual screening population and diagnostic workup population. The enrolled patient will undergo KBCT scans within 4 weeks of her screening or diagnostic mammography exam and before breast biopsy occurs if biopsy is needed.
Read the detailed description
Up to one thousand and twenty-eight (1028) patients from screening and diagnostic population will be enrolled and consented to participate in the study to create an enriched data set. These women will be enrolled from annual screening population and diagnostic workup population. The enrolled patient will undergo KBCT scans within 4 weeks of her screening or diagnostic mammography exam and before breast biopsy occurs if biopsy is needed.
Only women will be recruited for this study. Although men can get breast cancer, male breast cancer incidence is low and is not considered to be a great health issue. Thus, this study will exclude males with breast disease.
Women of ages 40 and above will be recruited for participation in the study. There are no enrollment restrictions based on race or ethnic origin. Patients enrolled in the study will have their standard-of-care screening mammography exams performed at the facility. A radiologic technologist, registered in radiography and mammography through the ARRT will perform the Screening Mammography procedure.
For patients enrolled in the study, a bilateral KBCT scan of both breasts (or unilateral scan if the subject has had a mastectomy) will be performed within 4 weeks of the mammography exam.
For all the subjects, the mammograms will be obtained as part of the standard of care and only the 3D KBCT imaging represents additional x-ray exposure.
The KBCT system employs a horizontally oriented gantry beneath a subject support table, which incorporates an x-ray tube at one end and a high-resolution, real-time flat panel detector (FPD) at the opposite end. The system is designed and built-in compliance with the national and international safety standards for medical equipment. A radiologic technologist, registered in radiography and mammography through the ARRT and who is also trained in KBCT acquisition, will position the breast and acquire the images.
For a KBCT scan, the subject lies prone on the support table. The breast of interest is placed through the opening in the table and the breast is positioned in the imaging field. The table sits above a motorized scanning arm carrying an x-ray source and image detector that allows a 360° rotational x-ray sequence in seconds. To acquire the full-volume scan of the breast, the KBCT gantry rotates 360o around the subject's breast, acquiring multiple pulsed projection images. Acquired image data is sent to a computer to perform 3D reconstruction. Specialized 3D visualization software constructs a three-dimensional model of the breast from the images taken during the rotational x-ray sequence. Once the data is reconstructed, it provides 3D isotropic images with the voxel size of ~(0.2mm)3 - ~(0.3mm)3 .The images can be displayed in any plane as well as a 3D rendering.
Our previous studies to-date has illustrated the capacity of the non-contrast KBCT to image the breast without structure overlap and with superior contrast resolution as compared with standard mammography imaging. The study results illustrate that the KBCT system is able to image the entire breast from axillary region to chest wall with clinically acceptable image quality and radiation dose comparable to conventional mammography. Cancers are better visualized as well as defined. In general, it is observed, that cancerous tissues absorb more x-rays than normal tissues, as determined by a higher Hounsfield Unit, but the Hounsfield Unit of some benign lesions can match that of cancer.
The KBCT images will be reviewed by the radiologists who join the study at each site. The radiologist will read the KBCT images and rate each case with "No Recall", "Recall" based on suspicious findings in the images.
- Conditions
- Breast Cancer
- Being tested
- CBBCT Imaging, Digital Mammography
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBBCT ImagingDevice
Both breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy.
Digital MammographyDevice
Both breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy.
| Study group | Role | What they receive |
|---|---|---|
| CBBCT Imaging Screening Patients | Experimental | Patient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of screening mammography. Receives: Device: CBBCT Imaging; Device: Digital Mammography |
| CBBCT Imaging Diagnostic Patients | Experimental | Patient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of diagnostic mammography. Receives: Device: CBBCT Imaging; Device: Digital Mammography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Radiation Dose
The radiation dose of CBBCT imaging and Mammography imaging
Measured: 3 months after the CBBCT imaging and Mammography imaging
Recall Rates
The overall recall rates of CBBCT imaging and Mammography imaging
Measured: 3 months after CBBCT image review and Mammography image review
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2021
- Study start30 Oct 2021
- Primary completion29 Dec 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Two groups of patients: Screening: patients who are scheduled for annual breast cancer screening. Diagnostic: patients who have an abnormality detected by Breast Self Exam, or Clinical Breast Exam (CBE), or have an abnormality detected by an imaging modality.
- Masking
- None (open label)
- Enrolment
- 1,024 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Koning Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Xiaohua Zhang, Ph.D., Study director, Koning Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05036096
- Sponsor's protocol ID
- 2021SCR
- Status last verified
- Feb 2026
- First submitted
- 25 Aug 2021
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cone Beam Breast CT for Breast Cancer Screening
- ClinicalTrials.gov ID
- NCT05036096
- Acronym / sponsor ID
- 2021SCR
- Conditions
- Breast Cancer
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,024 participants (estimated)
- Lead sponsor
- Koning CorporationIndustry (pharma, biotech, devices)
- Study start
- 30 Oct 2021 (actual)
- Primary completion
- 29 Dec 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 5 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Up to one thousand and twenty-eight (1028) patients from screening and diagnostic population will be enrolled and consented to participate in the study to create an enriched data set. These women will be enrolled from annual screening population and diagnostic workup population. The enrolled patient will undergo KBCT scans within 4 weeks of her screening or diagnostic mammography exam and before breast biopsy occurs if biopsy is needed.
Detailed description
Up to one thousand and twenty-eight (1028) patients from screening and diagnostic population will be enrolled and consented to participate in the study to create an enriched data set. These women will be enrolled from annual screening population and diagnostic workup population. The enrolled patient will undergo KBCT scans within 4 weeks of her screening or diagnostic mammography exam and before breast biopsy occurs if biopsy is needed.
Only women will be recruited for this study. Although men can get breast cancer, male breast cancer incidence is low and is not considered to be a great health issue. Thus, this study will exclude males with breast disease.
Women of ages 40 and above will be recruited for participation in the study. There are no enrollment restrictions based on race or ethnic origin. Patients enrolled in the study will have their standard-of-care screening mammography exams performed at the facility. A radiologic technologist, registered in radiography and mammography through the ARRT will perform the Screening Mammography procedure.
For patients enrolled in the study, a bilateral KBCT scan of both breasts (or unilateral scan if the subject has had a mastectomy) will be performed within 4 weeks of the mammography exam.
For all the subjects, the mammograms will be obtained as part of the standard of care and only the 3D KBCT imaging represents additional x-ray exposure.
The KBCT system employs a horizontally oriented gantry beneath a subject support table, which incorporates an x-ray tube at one end and a high-resolution, real-time flat panel detector (FPD) at the opposite end. The system is designed and built-in compliance with the national and international safety standards for medical equipment. A radiologic technologist, registered in radiography and mammography through the ARRT and who is also trained in KBCT acquisition, will position the breast and acquire the images.
For a KBCT scan, the subject lies prone on the support table. The breast of interest is placed through the opening in the table and the breast is positioned in the imaging field. The table sits above a motorized scanning arm carrying an x-ray source and image detector that allows a 360° rotational x-ray sequence in seconds. To acquire the full-volume scan of the breast, the KBCT gantry rotates 360o around the subject's breast, acquiring multiple pulsed projection images. Acquired image data is sent to a computer to perform 3D reconstruction. Specialized 3D visualization software constructs a three-dimensional model of the breast from the images taken during the rotational x-ray sequence. Once the data is reconstructed, it provides 3D isotropic images with the voxel size of ~(0.2mm)3 - ~(0.3mm)3 .The images can be displayed in any plane as well as a 3D rendering.
Our previous studies to-date has illustrated the capacity of the non-contrast KBCT to image the breast without structure overlap and with superior contrast resolution as compared with standard mammography imaging. The study results illustrate that the KBCT system is able to image the entire breast from axillary region to chest wall with clinically acceptable image quality and radiation dose comparable to conventional mammography. Cancers are better visualized as well as defined. In general, it is observed, that cancerous tissues absorb more x-rays than normal tissues, as determined by a higher Hounsfield Unit, but the Hounsfield Unit of some benign lesions can match that of cancer.
The KBCT images will be reviewed by the radiologists who join the study at each site. The radiologist will read the KBCT images and rate each case with "No Recall", "Recall" based on suspicious findings in the images.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Two groups of patients: Screening: patients who are scheduled for annual breast cancer screening. Diagnostic: patients who have an abnormality detected by Breast Self Exam, or Clinical Breast Exam (CBE), or have an abnormality detected by an imaging modality.
| Arm | Type | Receives |
|---|---|---|
| CBBCT Imaging Screening Patients | Experimental | Device: CBBCT Imaging, Device: Digital MammographyPatient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of screening mammography. |
| CBBCT Imaging Diagnostic Patients | Experimental | Device: CBBCT Imaging, Device: Digital MammographyPatient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of diagnostic mammography. |
Who may qualify
- Ages
- 30 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Female sex of any ethnicity
- Age 40 years or older
- Scheduled for a routine screening mammography exam within 4 weeks.
- Female sex of any ethnicity
- Age 30 years or older
Key exclusion criteria (17 listed)
- Pregnancy
- Lactation
- Unknown pregnancy status AND
- Women who are unable or unwilling to understand or to provide informed consent
- Women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBBCT ImagingBoth breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy. | Device | CBBCT Imaging Diagnostic Patients, CBBCT Imaging Screening Patients |
| Digital MammographyBoth breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy. | Device | CBBCT Imaging Diagnostic Patients, CBBCT Imaging Screening Patients |
Primary outcome
Radiation Dose
Time frame: 3 months after the CBBCT imaging and Mammography imaging
The radiation dose of CBBCT imaging and Mammography imaging
Recall Rates
Time frame: 3 months after CBBCT image review and Mammography image review
The overall recall rates of CBBCT imaging and Mammography imaging
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiaohua Zhang, Ph.D. study director
Koning Corporation
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CBBCT Imaging and Digital Mammography in people with Breast Cancer, run by Koning Corporation at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Radiation Dose (time frame: 3 months after the CBBCT imaging and Mammography imaging). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.